Variation in the UGT2B17 genotype, exemestane metabolism and menopause-related toxicities in the CCTG MAP.3 trial

ConclusionVariation in the metabolism of exemestane through theUGT2B17-mediated pathway is associated with subsequent risk of commonly reported symptoms in MAP.3.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research